## Couvelard Anne

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5418504/publications.pdf

Version: 2024-02-01

20759 32761 11,379 175 60 100 citations h-index g-index papers 192 192 192 12126 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary. Neuroendocrinology, 2012, 95, 157-176.	1.2	774
2	Regression of Liver Fibrosis after Biliary Drainage in Patients with Chronic Pancreatitis and Stenosis of the Common Bile Duct. New England Journal of Medicine, 2001, 344, 418-423.	13.9	393
3	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a Standardized Approach to the Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors and Their Prognostic Stratification. Neuroendocrinology, 2009, 90, 162-166.	1.2	313
4	Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy. Surgery, 2010, 148, 15-23.	1.0	301
5	Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels. New England Journal of Medicine, 2010, 363, 1621-1630.	13.9	263
6	Neuroendocrine tumors of midgut and hindgut origin: Tumorâ€nodeâ€metastasis classification determines clinical outcome. Cancer, 2011, 117, 3332-3341.	2.0	254
7	Pancreatic Endocrine Tumors: Tumor Blood Flow Assessed with Perfusion CT Reflects Angiogenesis and Correlates with Prognostic Factors < sup > 1 < /sup > . Radiology, 2009, 250, 407-416.	3.6	224
8	Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma. Gastroenterology, 2012, 143, 664-674.e6.	0.6	218
9	Natural History of Intraductal Papillary Mucinous Tumors of the Pancreas: Actuarial Risk of Malignancy. Clinical Gastroenterology and Hepatology, 2006, 4, 460-468.	2.4	215
10	Microadenomatosis of the Endocrine Pancreas in Patients With and Without the Multiple Endocrine Neoplasia Type 1 Syndrome. American Journal of Surgical Pathology, 2006, 30, 560-574.	2.1	207
11	Report of a fatal case of dengue infection with hepatitis: Demonstration of dengue antigens in hepatocytes and liver apoptosis. Human Pathology, 1999, 30, 1106-1110.	1.1	186
12	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification. Neuroendocrinology, 2017, 105, 196-200.	1.2	178
13	Outcome of Patients With Type 1 or 2 Autoimmune Pancreatitis. American Journal of Gastroenterology, 2011, 106, 151-156.	0.2	174
14	Differences in Alimentary Glucose Absorption and Intestinal Disposal of Blood Glucose After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. Gastroenterology, 2016, 150, 454-464.e9.	0.6	171
15	Obesity and Fatty Pancreatic Infiltration Are Risk Factors for Pancreatic Precancerous Lesions (PanIN). Clinical Cancer Research, 2015, 21, 3522-3528.	<b>3.</b> 2	165
16	Pattern and Clinical Predictors of Lymph Node Involvement in Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNETs). JAMA Surgery, 2013, 148, 932.	2.2	154
17	Macrocystic pancreatic cystadenoma: the role of EUS and cyst fluid analysis in distinguishing mucinous and serous lesions. Gastrointestinal Endoscopy, 2004, 59, 823-829.	0.5	144
18	Retention of Plasmodium falciparum ring-infected erythrocytes in the slow, open microcirculation of the human spleen. Blood, 2008, 112, 2520-2528.	0.6	141

#	Article	IF	CITATIONS
19	Intraductal papillary mucinous tumors of the pancreas: the preoperative value of cytologic and histopathologic diagnosis. Gastrointestinal Endoscopy, 2003, 58, 701-706.	0.5	140
20	Clinical and Autopsy Diagnoses in the Intensive Care Unit. Archives of Internal Medicine, 2004, 164, 389.	4.3	137
21	Preoperative CT Scan Helps to Predict the Occurrence of Severe Pancreatic Fistula After Pancreaticoduodenectomy. Annals of Surgery, 2012, 256, 139-145.	2.1	133
22	Smooth muscle cell modulation and cytokine overproduction in varicose veins. Anin situ study. Journal of Pathology, 2001, 193, 398-407.	2.1	128
23	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. Neuroendocrinology, 2017, 105, 201-211.	1.2	127
24	Rare Functioning Pancreatic Endocrine Tumors. Neuroendocrinology, 2006, 84, 189-195.	1.2	124
25	Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist, 2016, 21, 1191-1199.	1.9	123
26	Intraductal Papillary Mucinous Neoplasms of the Pancreas: Performance of Pancreatic Fluid Analysis for Positive Diagnosis and the Prediction of Malignancy. American Journal of Gastroenterology, 2008, 103, 2871-2877.	0.2	122
27	Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well-Differentiated Tumour/Carcinoma of the Appendix and Goblet Cell Carcinoma. Neuroendocrinology, 2008, 87, 20-30.	1.2	119
28	Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Neuroendocrinology, 2017, 105, 412-425.	1.2	119
29	Ex vivo perfusion of human spleens maintains clearing and processing functions. Blood, 2006, 107, 3745-3752.	0.6	117
30	Morphologic Changes in Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Midterm Follow-Up Study. Clinical Gastroenterology and Hepatology, 2008, 6, 807-814.	2.4	117
31	Pancreaticoduodenectomy with Mesentericoportal Vein Resection for Adenocarcinoma of the Pancreatic Head. World Journal of Surgery, 2006, 30, 1526-1535.	0.8	110
32	Two-step Surgery for Synchronous Bilobar Liver Metastases From Digestive Endocrine Tumors: A Safe Approach for Radical Resection. Annals of Surgery, 2008, 247, 659-665.	2.1	107
33	Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions. Journal of Pathology, 2002, 197, 632-637.	2.1	102
34	Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature. Cancer Research, 2016, 76, 7181-7193.	0.4	99
35	Parenchyma-Sparing Resections for Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2012, 16, 2045-2055.	0.9	97
36	Reappraisal of Central Pancreatectomy. JAMA Surgery, 2014, 149, 356.	2.2	92

#	Article	IF	Citations
37	The long term risk of malignancy in patients with branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreatology, 2012, 12, 198-202.	0.5	91
38	Hepatic Arterial Embolization versus Chemoembolization in the Treatment of Liver Metastases from Well-Differentiated Midgut Endocrine Tumors: A Prospective Randomized Study. Neuroendocrinology, 2012, 96, 294-300.	1.2	89
39	Expression of integrins during liver organogenesis in humans. Hepatology, 1998, 27, 839-847.	3.6	88
40	Frozen Sectioning of the Pancreatic Cut Surface During Resection of Intraductal Papillary Mucinous Neoplasms of the Pancreas Is Useful and Reliable. Annals of Surgery, 2005, 242, 774-780.	2.1	88
41	The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. European Journal of Endocrinology, 2006, 155, 849-857.	1.9	87
42	Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors. Clinical Cancer Research, 2008, 14, 6634-6639.	3.2	84
43	Targeting the Ras–ERK pathway in pancreatic adenocarcinoma. Cancer and Metastasis Reviews, 2013, 32, 147-162.	2.7	83
44	Tumor Heterogeneity in Pancreatic Adenocarcinoma. Pathobiology, 2018, 85, 64-71.	1.9	83
45	Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Modern Pathology, 2009, 22, 273-281.	2.9	82
46	State of the art and future directions of pancreatic ductal adenocarcinoma therapy., 2015, 155, 80-104.		82
47	Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. Journal of Hepatology, 2001, 34, 850-857.	1.8	81
48	Chromosome 1p loss: A favorable prognostic factor in low-grade gliomas. Annals of Neurology, 2005, 58, 322-326.	2.8	80
49	Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. European Radiology, 2017, 27, 1748-1759.	2.3	80
50	Relationship between vascular development and vascular differentiation during liver organogenesis in humans. Journal of Hepatology, 2002, 37, 730-740.	1.8	78
51	Parenchyma-Sparing Pancreatectomy for Presumed Noninvasive Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery, 2014, 260, 364-371.	2.1	78
52	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. Neuroendocrinology, 2018, 107, 375-386.	1.2	78
53	Endocrine Pancreatic Tumors in von Hippel-Lindau Disease. Pancreas, 2008, 37, 85-93.	0.5	75
54	Clinical and Morphological Features of Duodenal Cystic Dystrophy in Heterotopic Pancreas. American Journal of Gastroenterology, 2007, 102, 871-879.	0.2	74

#	Article	IF	Citations
55	Adenomyoma and Adenomyomatous Hyperplasia of the Vaterian System: Clinical, Pathological, and New Immunohistochemical Features of 13 Cases. Modern Pathology, 2003, 16, 530-536.	2.9	72
56	Identification of Potential Therapeutic Targets by Gene-Expression Profiling in Pancreatic Endocrine Tumors. Gastroenterology, 2006, 131, 1597-1610.	0.6	72
57	Glucagon Cell Adenomatosis: A Newly Recognized Disease of the Endocrine Pancreas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 213-217.	1.8	68
58	Mucinous Cystic Neoplasms of the Pancreas: Definition of Preoperative Imaging Criteria for High-Risk Lesions. Pancreatology, 2011, 11, 495-499.	0.5	66
59	Immunoglobulin G4 Immunostaining of Gastric, Duodenal, or Colonic Biopsies Is Not Helpful for the Diagnosis of Autoimmune Pancreatitis. Clinical Gastroenterology and Hepatology, 2012, 10, 91-94.	2.4	66
60	Glucagon Cell Hyperplasia and Neoplasia With and Without Glucagon Receptor Mutations. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E783-E788.	1.8	65
61	Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors. European Journal of Gastroenterology and Hepatology, 2013, 25, 232-238.	0.8	62
62	Sporadic nonfunctioning pancreatic neuroendocrine tumors: Prognostic significance of incidental diagnosis. Surgery, 2014, 155, 13-21.	1.0	62
63	The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocrine-Related Cancer, 2022, 29, $1\text{-}14$ .	1.6	62
64	Prevalence of Extrapancreatic Cancers in Patients With Histologically Proven Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Case-Control Study. American Journal of Gastroenterology, 2008, 103, 2878-2882.	0.2	61
65	Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients. Clinical Cancer Research, 2012, 18, 2838-2849.	3.2	61
66	Pancreatic Endocrine Microadenomatosis in Patients With von Hippel-Lindau Disease. American Journal of Surgical Pathology, 2009, 33, 739-748.	2.1	60
67	Malignant Intraductal Papillary Mucinous Neoplasm of the Pancreas: In Situ versus Invasive Carcinomaâ€"Surgical Resectability. Radiology, 2007, 245, 483-490.	3.6	59
68	Reappraisal of pancreatic enucleations: A single-center experience of 126 procedures. Surgery, 2015, 158, 201-210.	1.0	59
69	Focal nodular hyperplasia of the liver: Composition of the extracellular matrix and expression of cell-cell and cell-matrix adhesion molecules. Human Pathology, 1995, 26, 1114-1125.	1.1	53
70	Impaired E-Cadherin Expression and Glutamine Synthetase Overexpression in Solid Pseudopapillary Neoplasm of the Pancreas. Pancreas, 2008, 36, 80-83.	0.5	52
71	Is Idiopathic Chronic Pancreatitis an Autoimmune Disease?. Clinical Gastroenterology and Hepatology, 2005, 3, 903-909.	2.4	51
72	Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors?. Surgery, 2009, 145, 69-75.	1.0	49

#	Article	IF	CITATIONS
73	Surface Area Loss and Increased Sphericity Account for the Splenic Entrapment of Subpopulations of Plasmodium falciparum Ring-Infected Erythrocytes. PLoS ONE, 2013, 8, e60150.	1.1	49
74	Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2010, 17, 847-856.	1.6	48
75	CD10 expression in pancreatic endocrine tumors: correlation with prognostic factors and survival. Human Pathology, 2006, 37, 802-808.	1.1	46
76	Acute Pancreatitis in Patients Operated on for Intraductal Papillary Mucinous Neoplasms of the Pancreas. Pancreas, 2010, 39, 658-661.	0.5	46
77	Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place. Annals of Surgery, 2015, 262, 384-388.	2.1	46
78	Acinar-to-Ductal Metaplasia Induced by Transforming Growth Factor Beta Facilitates KRAS G12D -driven Pancreatic Tumorigenesis. Cellular and Molecular Gastroenterology and Hepatology, 2017, 4, 263-282.	2.3	46
79	Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Targeted Oncology, 2012, 7, 127-133.	1.7	45
80	Endothelial cell heterogeneity in the normal human liver acinus: <i>in situ</i> ii immunohistochemical demonstration. Liver, 1994, 14, 113-123.	0.1	43
81	Pathology Analysis Reveals That Dysplastic Pancreatic Ductal Lesions Are Frequent in Patients With Hereditary Pancreatitis. Clinical Gastroenterology and Hepatology, 2010, 8, 206-212.	2.4	43
82	Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics?. Digestive and Liver Disease, 2015, 47, 973-977.	0.4	43
83	High prevalence of IgG4-related lymphoplasmacytic infiltrative disorder in 25 patients with orbital inflammation: a retrospective case series. British Journal of Ophthalmology, 2013, 97, 999-1004.	2.1	42
84	Endocrine Tumor and Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Fortuitous Association?. Pancreas, 2005, 31, 79-83.	0.5	41
85	Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms. Neuroendocrinology, 2018, 107, 24-31.	1.2	41
86	Surgery for small-bowel neuroendocrine tumors: Is there any benefit of the laparoscopic approach?. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 1720-1726.	1.3	39
87	Sensing of red blood cells with decreased membrane deformability by the human spleen. Blood Advances, 2018, 2, 2581-2587.	2.5	39
88	No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene, 2001, 20, 5059-5061.	2.6	38
89	Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma. Head and Neck, 2013, 35, 1819-1828.	0.9	38
90	Endoscopic, transanal, laparoscopic, and transabdominal management of rectal neuroendocrine tumors. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101293.	2.2	37

#	Article	IF	CITATIONS
91	Integrin up-regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C. Journal of Pathology, 2001, 195, 473-481.	2.1	36
92	Metachronous Hormonal Syndromes in Patients With Pancreatic Neuroendocrine Tumors. Annals of Internal Medicine, 2015, 162, 682-689.	2.0	36
93	Long-Term Evaluation of Biliary Reflux After Experimental One-Anastomosis Gastric Bypass in Rats. Obesity Surgery, 2017, 27, 1119-1122.	1.1	35
94	Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey among French Pathologists (the PRONET Study). Neuroendocrinology, 2017, 105, 67-76.	1.2	35
95	Oxidative Stress Induced by Inactivation of TP53INP1 Cooperates with KrasG12D to Initiate and Promote Pancreatic Carcinogenesis in the Murine Pancreas. American Journal of Pathology, 2013, 182, 1996-2004.	1.9	34
96	Lessons From McCune-Albright Syndrome–Associated Intraductal Papillary Mucinous Neoplasms. JAMA Surgery, 2014, 149, 858.	2.2	33
97	Determination of Angptl4 mRNA as a Diagnostic Marker of Primary and Metastatic Clear Cell Renal-Cell Carcinoma. PLoS ONE, 2010, 5, e10421.	1.1	33
98	Temozolomide: A Safe and Effective Treatment for Malignant Digestive Endocrine Tumors. Neuroendocrinology, 2009, 90, 67-72.	1.2	31
99	Dual Roles for CXCL4 Chemokines and CXCR3 in Angiogenesis and Invasion of Pancreatic Cancer. Cancer Research, 2016, 76, 6507-6519.	0.4	31
100	Endocannabinoid Receptor-1 and Sympathetic Nervous System Mediate the Beneficial Metabolic Effects of Gastric Bypass. Cell Reports, 2020, 33, 108270.	2.9	31
101	Biological and Prognostic Relevance of Mitogen-Activated Protein Kinases in Pancreatic Adenocarcinoma. Pancreas, 2012, 41, 416-421.	0.5	30
102	Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue. Oral Oncology, 2012, 48, 1263-1271.	0.8	30
103	Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset. Cancers, 2019, 11, 126.	1.7	29
104	Early expression of adhesion molecules after lung transplantation: Evidence for a role of aggregated P-selectin-positive platelets in human primary graft failure. Journal of Heart and Lung Transplantation, 2004, 23, 1087-1092.	0.3	28
105	Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas. Human Pathology, 2011, 42, 1702-1709.	1.1	28
106	Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology. Neuroendocrinology, 2021, 111, 158-169.	1.2	28
107	Helical CT of Pancreatic Endocrine Tumors. Journal of Computer Assisted Tomography, 2002, 26, 728-733.	0.5	27
108	Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. Neuro-Oncology, 2014, 16, 1196-1209.	0.6	27

#	Article	lF	CITATIONS
109	O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET). Digestive and Liver Disease, 2019, 51, 595-599.	0.4	27
110	CD31 Expression in Benign, Borderline, and Malignant Epithelial Ovarian Tumors: An Immunohistochemical and Serological Analysis. Gynecologic Oncology, 1998, 71, 122-127.	0.6	26
111	Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Targeted Oncology, 2012, 7, 173-181.	1.7	26
112	CT and MR imaging of multilocular acinar cell cystadenoma: comparison with branch duct intraductal papillary mucinous neoplasia (IPMNs). European Radiology, 2014, 24, 2128-2136.	2.3	26
113	Pancreatic Intraepithelial Neoplasia in Patients With Intraductal Papillary Mucinous Neoplasms. Pancreas, 2013, 42, 1262-1266.	0.5	24
114	Impact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice. PLoS ONE, 2017, 12, e0169908.	1.1	23
115	Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need. Neuroendocrinology, 2019, 108, 45-53.	1.2	22
116	In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin- $\hat{l}^24$ as markers of malignant intraductal pancreatic mucinous neoplasms. Pancreatology, 2014, 14, 117-124.	0.5	21
117	High câ€Met expression in stage l– <scp>II</scp> pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Histopathology, 2015, 67, 664-676.	1.6	21
118	Remodeling of the Residual Gastric Mucosa after Roux-En-Y Gastric Bypass or Vertical Sleeve Gastrectomy in Diet-Induced Obese Rats. PLoS ONE, 2015, 10, e0121414.	1.1	21
119	Hypoxia Pathways and Cellular Stress Activate Pancreatic Stellate Cells: Development of an Organotypic Culture Model of Thick Slices of Normal Human Pancreas. PLoS ONE, 2013, 8, e76229.	1.1	20
120	Familial intraductal papillary mucinous neoplasms of the pancreas. Digestive and Liver Disease, 2012, 44, 442-446.	0.4	19
121	Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors. Neuroendocrinology, 2016, 103, 495-499.	1.2	19
122	Astaxanthin Complexes to Attenuate Muscle Damage after In Vivo Femoral Ischemia-Reperfusion. Marine Drugs, 2019, 17, 354.	2.2	19
123	Biomarkers of Response to Etoposide-Platinum Chemotherapy in Patients with Grade 3 Neuroendocrine Neoplasms. Cancers, 2021, 13, 643.	1.7	19
124	Proteomic Assessment of Markers for Malignancy in the Mucus of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Pancreas, 2012, 41, 169-174.	0.5	18
125	18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation. Neuroendocrinology, 2018, 106, 274-282.	1.2	18
126	Preclinical Evaluation of 68Ga-DOTA-NT-20.3: A Promising PET Imaging Probe To Discriminate Human Pancreatic Ductal Adenocarcinoma from Pancreatitis. Molecular Pharmaceutics, 2019, 16, 2776-2784.	2.3	18

#	Article	IF	Citations
127	The Expression of the Hypoxia Markers CA9 and CXCR4 Is Correlated with Survival in Patients with Neuroendocrine Tumours of the Ileum. Neuroendocrinology, 2012, 95, 214-222.	1.2	16
128	Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors. Digestive and Liver Disease, 2019, 51, 1720-1724.	0.4	16
129	ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology. Journal of Neuroendocrinology, 2022, 34, e13100.	1.2	16
130	Gastroenteropancreatic neuroendocrine tumors: indications for and pitfalls of frozen section examination. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 441-448.	1.4	15
131	Does tobacco influence the natural history of autoimmune pancreatitis?. Pancreatology, 2014, 14, 284-288.	0.5	15
132	Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE). Neuroendocrinology, 2018, 106, 38-46.	1,2	15
133	Predicting the efficacy of surgery for pain relief in patients with alcoholic chronic pancreatitis. Surgery, 2018, 164, 1064-1070.	1.0	14
134	Critical appraisal of MGMT in digestive NET treated with alkylating agents. Endocrine-Related Cancer, 2020, 27, R391-R405.	1.6	14
135	Correlation between patterns of DNA mismatch repair hmlh1 and hmsh2 protein expression and progression of dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 235-238.	1.4	13
136	EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins. Journal of Clinical Pathology, 2014, 67, 295-300.	1.0	13
137	Image of the Month. Gastroenterology, 2005, 129, 1150-1365.	0.6	12
138	Id3 modulates cellular localization of bHLH Ptf1â€p48 protein. International Journal of Cancer, 2011, 129, 295-306.	2.3	12
139	Human allograft vein failure: Immunohistochemical arguments supporting the involvement of an immune-mediated mechanism. Human Pathology, 1995, 26, 1313-1320.	1.1	11
140	Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors. Pancreas, 2017, 46, 631-638.	0.5	11
141	Recurrence after surgical resection of gastrinoma. European Journal of Gastroenterology and Hepatology, 2012, 24, 1.	0.8	11
142	Granular Cell Tumor of the Pancreas. Pancreas, 2005, 31, 296-298.	0.5	10
143	Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features. Cancers, 2021, 13, 1234.	1.7	10
144	Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. Endocrine-Related Cancer, 2021, 28, 549-561.	1.6	10

#	Article	IF	Citations
145	Cytomegalovirus proctitis as a complication of COVID-19 with immunosuppressive treatments. IDCases, 2021, 24, e01111.	0.4	10
146	Epidermoid carcinoma complicating esophageal lichen planus without cutaneous or oral involvement. Gastrointestinal Endoscopy, 2011, 74, 221-223.	0.5	8
147	Tumoral epithelial and stromal expression of SMAD proteins in pancreatic ductal adenocarcinomas. Journal of Hepato-Biliary-Pancreatic Sciences, 2013, 20, 294-302.	1.4	8
148	An atypical persistent eruption of adultâ€onset Still's disease with neutrophilic urticarial dermatosisâ€like dermal features: A case report and review of the literature. Journal of Cutaneous Pathology, 2018, 45, 793-799.	0.7	8
149	Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?. Neuroendocrinology, 2021, 111, 170-177.	1.2	8
150	Mucinous cystadenoma with mesenchymal over-growth: a new variant among pancreatic mucinous cystadenomas?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 203-5.	1.4	7
151	Difficult Diagnosis of Atypical Cystic Pancreatic Lesions in von Hippel-Lindau Disease. Journal of Computer Assisted Tomography, 2010, 34, 140-145.	0.5	7
152	Long-term consequences of one anastomosis gastric bypass on esogastric mucosa in a preclinical rat model. Scientific Reports, 2020, 10, 7393.	1.6	7
153	Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels. Obstetrical and Gynecological Survey, 2011, 66, 99-101.	0.2	6
154	Somatostatin Receptor Subtype 2 Expression and Somatostatin Receptor Scintigraphy Positivity in Pancreatic Serous Cystadenomas. Pancreas, 2015, 44, 672-674.	0.5	6
155	An update on the development of concepts, diagnostic criteria, and challenging issues for neuroendocrine neoplasms across different digestive organs. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, , 1.	1.4	6
156	Neuroendocrine tumours of the pancreas: recent developments in staging and grading. Diagnostic Histopathology, 2012, 18, 1-7.	0.2	5
157	Human chorionic gonadotrophin beta expression in malignant Barrett?s oesophagus. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 279-284.	1.4	4
158	A clear cell malignant gastrinoma of the pancreas with cytoplasmic accumulation of lipid droplets. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 105-106.	1.4	4
159	Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2021, 28, 457-466.	1.6	4
160	Akt pathway protein expression in gastrointestinal Kaposi sarcomas: relevance for tumor biology. Apmis, 2014, 122, 518-525.	0.9	3
161	Glucagonoma., 2015,, 81-87.		3
162	A gastric MANEC with an adenocarcinoma of fundic-gland type as exocrine component. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 673-678.	1.4	3

#	Article	IF	CITATIONS
163	Risk of Perforated Colonic Diverticulitis in Patients With Chronic Kidney Disease Requiring Sodium Polystyrene Sulfonate: Not to Be Forgotten. American Journal of Gastroenterology, 2019, 114, 1003-1005.	0.2	3
164	Molecular deciphering of primary liver neuroendocrine neoplasms confirms their distinct existence with foregutâ€like profile. Journal of Pathology, 2022, 258, 58-68.	2.1	3
165	Pancreatic Intraepithelial Neoplasia Is Associated With Chronic Pancreatitis Due to Serine Protease Inhibitor Kazal Type 1 and Cystic Fibrosis Transmembrane Conductance Regulator Mutations. Pancreas, 2010, 39, 947-948.	0.5	2
166	Xanthomatous Posttraumatic Fibro-Osseous Lesion of the Rib: A Rare and Underrecognized Entity. Case Report and Literature Review. International Journal of Surgical Pathology, 2017, 25, 640-643.	0.4	2
167	Peritoneal Pulse Granulomas With Spiral Bodies Mimicking Peritoneal Carcinomatosis: A Case Report. International Journal of Surgical Pathology, 2018, 26, 561-563.	0.4	2
168	Response to "Obesity potentiates the growth and dissemination of pancreatic cancer― Surgery, 2010, 147, 174.	1.0	1
169	Could pancreatic grade 3 neuroendocrine tumors really behave similarly to neuroendocrine carcinomas following resection?. Hpb, 2020, 22, 792.	0.1	1
170	Digestive and lung high-grade neuroendocrine neoplasms: Update and challenging issues. Current Opinion in Endocrine and Metabolic Research, 2021, 18, 224-229.	0.6	1
171	Pathological Evaluation and Classification of Digestive Neuroendocrine Tumours., 2015,, 59-76.		1
172	Pathology. Annales D'Endocrinologie, 2013, 74, 203-206.	0.6	0
173	Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine Tumors (PNETs) Treatment., 2014,, 167-180.		0
174	O-positive blood type is associated with prolonged recurrence-free survival following curative resection of pancreatic neuroendocrine tumors. Pancreatology, 2020, 20, 1718-1722.	0.5	0
175	Imaging of Neuroendocrine Tumors and Challenges in Response Evaluation for Targeted Therapies. , 2014, , 155-165.		O